dexfenfluramine (Redux) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dexfenfluramine, marketed as dexfenfluramine hydrochloride under the name Redux, is a serotonergic anorectic drug: it reduces appetite by increasing the amount of extracellular serotonin in the brain. It is the d-enantiomer of fenfluramine and is structurally similar to amphetamine, but lacks any psychologically stimulating effects.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

adifax | dexfenfluramina | dexfenfluramine | dexfenfluramine hcl | dexfenfluramine hydrochloride | dexfenfluraminum | dextrofenfluramine | d-fenfluramine | d-n-ethyl-alpha-methyl-m-trifluoromethylphenethylamine | (+)-fenfluramine | redux | s-5614 hcl | (s)-fenfluramine | (s)-n-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine

Organizations (2)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Overview

  • Highest Phase: N/A
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue